A5070136704- Hepatitis C virus research
- Maternal and Perinatal Health Interventions
- Liver Disease Diagnosis and Treatment
- Health Systems, Economic Evaluations, Quality of Life
- Atrial Fibrillation Management and Outcomes
- Hepatitis B Virus Studies
- Total Knee Arthroplasty Outcomes
- Orthopaedic implants and arthroplasty
- Healthcare Policy and Management
- Orthopedic Infections and Treatments
- Treatment of Major Depression
- Mental Health Treatment and Access
- Patient Satisfaction in Healthcare
- Antibiotic Use and Resistance
- SARS-CoV-2 and COVID-19 Research
- Global Maternal and Child Health
- Anxiety, Depression, Psychometrics, Treatment, Cognitive Processes
- Global Health Care Issues
- Bacterial Identification and Susceptibility Testing
- Obesity and Health Practices
- Maternal and fetal healthcare
- Social Issues and Policies
- Bariatric Surgery and Outcomes
- SARS-CoV-2 detection and testing
- Cardiac Imaging and Diagnostics
Clifton Hospital
2023
Health Information and Quality Authority
2019-2022
Health and Safety Authority
2019-2022
University of Bristol
2016-2019
University College Cork
2013-2017
Depression is usually managed in primary care, but most antidepressant trials are of patients from secondary care mental health services, with eligibility criteria based on diagnosis and severity depressive symptoms. Antidepressants now used a much wider group people than previous regulatory trials. We investigated the clinical effectiveness sertraline symptoms ranging mild to severe tested role duration treatment response.The PANDA study was pragmatic, multicentre, double-blind,...
Abstract Background Population-adjusted indirect comparison using parametric Simulated Treatment Comparison (STC) has had limited application to survival outcomes in unanchored settings. Matching-Adjusted Indirect (MAIC) is commonly used but does not account for violation of proportional hazards or enable extrapolations survival. We developed and applied a novel methodology STC compared overall (OS) progression-free (PFS) lenvatinib plus pembrolizumab (LEN + PEM) against nivolumab ipilimumab...
Elective repeat caesarean delivery (ERCD) rates have been increasing worldwide, thus prompting obstetric discourse on the risks and benefits for mother infant. Yet, these also major economic implications health care system. Given dearth of information cost-effectiveness related to mode delivery, aim this paper was perform an evaluation costs short-term maternal consequences associated with a trial labour after one previous compared ERCD low risk women in Ireland.Using decision analytic...
Depending on obstetric risk, maternity care may be provided in one of two locations at hospital level: a consultant-led unit (CLU) or midwifery-led (MLU). Care MLU is sparsely Ireland, comprising as few units out total 21 units. Given its potential for greater efficiencies and cost-savings the state, there has been an increased interest to expand MLUs Ireland. Yet, very little known about women's preferences care, whether they would utilise this service when presented with choice delivering...
In many countries, there has been a considerable shift towards providing more woman-centred maternity service, which affords greater consumer choice. Maternity service provision in Ireland is set to follow this trend with policymakers committed improving maternal choice at hospital level. However, women's preferences for care are unknown, as the expected demand new services. paper, we used discrete experiment (DCE) (1) investigate strengths of preference different features care; (2) predict...
Direct-acting antivirals are successful in curing hepatitis C virus infection more than 95% of patients treated for 12 weeks, but they expensive. Shortened treatment durations, which may have lower cure rates, been proposed to reduce costs.
The Irish government has committed to expand midwifery-led care alongside consultant-led nationally, although very little is known about the potential net benefits of this reconfiguration. To formally compare costs and major models in Ireland, with a view informing priority setting using contingent valuation technique cost-benefit analysis. A marginal payment scale willingness-to-pay question was adopted from an ex ante perspective. 450 pregnant women were invited participate study. Cost...
Approximately 60% of antibiotics issued in primary care are for acute respiratory tract infections (RTIs), which largely self-limiting and do not require antibiotics. Point-of-care testing (POCT) devices that measure C-reactive protein (CRP)-a biomarker infection-can be used to guide prescribing decisions.We evaluated the cost-effectiveness budget impact a national CRP POCT program antibiotic RTIs Ireland.We compared with without enhanced communication skills training general practitioners...
Background Despite a growing number of prescriptions for antidepressants (over 70 million in 2018), there is uncertainty about when people with depression might benefit from antidepressant medication and concern that are prescribed unnecessarily. Objectives The main objective the PANDA (What indications Prescribing ANtiDepressAnts will lead to clinical benefit?) research programme was provide more guidance likely depression. We aimed estimate minimal clinically important difference commonly...
<h3>Objective</h3> To perform an economic evaluation on the costs and maternal health consequences associated with a trial of labour (TOL) after one previous caesarean delivery compared elective repeat (ERCD) for low risk women in Irish context. <h3>Methods</h3> Incidence rates adverse outcomes following TOL ERCD were unavailable Ireland, therefore representative estimates derived from review international literature pooled data. Delivery/procedure micro-costed based information primary data...
Antidepressants are commonly prescribed for depression, but it is unclear whether treatment efficacy depends on severity and duration of symptoms how prescribing might be targeted cost-effectively.
Direct-acting antivirals containing nonstructural protein 5A (NS5A) inhibitors administered over 8 to 12 weeks are effective in ∼95% of patients with hepatitis C virus. Nevertheless, resistant NS5A have lower cure rates (<85%); for these patients, treatment produces greater than 95%. We evaluated the lifetime cost-effectiveness testing resistance at baseline and optimizing duration accordingly genotype 1 noncirrhotic treatment-naïve from perspective UK National Health Service.A...